2025-03-31 18:39:52
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Bliss GVS Pharma Ltd posts jump in consolidated Q2 FY24 PAT to Rs. 42.30 crores
Posted On : 2023-11-02 09:14:47( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 224.4789 crores during the period ended September 30, 2023 as compared to Rs. 164.6344 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 42.3065 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 14.6851 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 3.98 for the period ended September 30, 2023 as compared to Rs. 1.38 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 224.4789 crs | ₹164.6344 crs |  36.35% |
| Net Profit | ₹42.3065 crs | ₹14.6851 crs | 188.09% |
| EPS | ₹3.98 | ₹1.38 | 188.41% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 224.4789 crores during the period ended September 30, 2023 as compared to Rs.174.5810 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.42.3065 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.13.8538 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.3.98 for the period ended September 30, 2023 as compared to Rs.1.31 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 224.4789 crs | ₹174.5810 crs | 28.58% |
| Net Profit | ₹42.3065 crs | ₹13.8538 crs | 205.38% |
| EPS | ₹3.98 | ₹1.31 | 203.82% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.389.1133 crores during the 6 Months period ended September 30, 2023 as compared to Rs.370.2535 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.56.9916 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.39.5731 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.5.37 for the 6 Months period ended September 30, 2023 as compared to Rs.3.75 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹389.1133 crs | ₹370.2535 crs | 5.09% |
| Net Profit | ₹56.9916 crs | ₹39.5731 crs | 44.02% |
| EPS | ₹5.37 | ₹3.75 | 43.20% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 84.09 as compared to the previous close of Rs. 84.07. The total number of shares traded during the day was 7698 in over 127 trades.
The stock hit an intraday high of Rs. 85.65 and intraday low of 83.85. The net turnover during the day was Rs. 652615.00.
